Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | CHUK | O15111 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3249218 | 0.98 | MAPT (0.61) | MAPTALDH1A1IKBKBCHUKMEN1 | |
| SCHEMBL1953550 | 0.94 | ALDH1A1 (0.63) | MAPTALDH1A1IKBKBCHUKMEN1 | |
| SCHEMBL15009887 | 0.84 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2AGAAEPHX2 | |
| SCHEMBL4384981 | 0.83 | CNR1 (0.54) | MAPTALDH1A1IKBKBCHUKGAA | |
| SCHEMBL732932 | 0.83 | LMNA (0.71) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL28254937 | 0.83 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2AGAAEPHX2 | |
| SCHEMBL2306745 | 0.81 | HTT (0.65) | MAPTALDH1A1GAAPKMHSD11B1 | |
| SCHEMBL1797016 | 0.81 | MAPT (0.69) | MAPTALDH1A1MEN1KMT2APKM | |
| SCHEMBL24295449 | 0.80 | EPHX2 (0.75) | ALDH1A1MEN1KMT2AGAAEPHX2 | |
| SCHEMBL12655864 | 0.80 | KMT2A (0.63) | MAPTALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015066-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-117720528-A | Oxadiazole sulfonamide compound containing pyrazole structure, and preparation method and application thereof | 贵州大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-114634465-B | Pentadienone derivative containing sulfonyl piperazine as well as preparation method and application thereof | 贵州大学 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022130352-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2022-06-23 | — | — | WO | disclosed |
| CN-114634465-A | Sulfonyl piperazine-containing pentadiene ketone derivative and preparation method and application thereof | 贵州大学 | 2022-06-17 | — | — | CN | disclosed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | disclosed |
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007073-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2010007072-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007072-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007074-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | MAPT 1474/4885ALDH1A1 3984/4885IKBKB 2464/4885 |
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | MAPT 1474/4885ALDH1A1 3984/4885IKBKB 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.